Autophagy regulating kinases as potential therapeutic targets for age-related macular degeneration

Future Medicinal Chemistry

Volumn 4, Issue 17, 2012, Pages 2153-2161

  Kaarniranta, Kai ^a,b   Kauppinen, Anu ^a   Blasiak, Janusz ^c   Salminen, Antero ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE PHOSPHORIBOSYLTRANSFERASE; HISTONE DEACETYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; REACTIVE OXYGEN METABOLITE; RHEB PROTEIN; SIRTUIN 1; SIRTUIN 2;

AGED; AGING; AUTOPHAGY; DEVELOPED COUNTRY; DISEASE COURSE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; HOMEOSTASIS; HUMAN; HYPOXIA; INFLAMMATION; LYSOSOME; OXIDATIVE STRESS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIGNAL TRANSDUCTION; VISUAL IMPAIRMENT;

ANIMALS; AUTOPHAGY; DRUG DISCOVERY; HUMANS; MACULA LUTEA; MACULAR DEGENERATION; MOLECULAR TARGETED THERAPY; PROTEIN KINASES; SIRTUINS; TOR SERINE-THREONINE KINASES;

EID: 84870424383     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.169     Document Type: Review

References (111)

1. Pascolini D, Mariotti SP, Pokharel GP et al. Global update of available data on visual impairment: a compilation of population based prevalence studies. Ophthalmic. Epidemiol. 11(2), 67-115 (2004).
2. Gordois A, Pezzullo L, Cutler H et al. An estimation of the worldwide economic and health burden of visual impairment. Global Public Health 7(5), 465-481 (2012).
3. Gehrs KM, Anderson DH, Johnson LV et al. Age related macular degeneration. Emerging pathogenetic and therapeutic concepts. Ann. Med. 38(7), 450-471 (2006).
4. Friedman DS, O'Colmain BJ, Munoz B et al. Prevalence of age related macular degeneration in the United States. Arch. Ophthalmol. 122(4), 564-572 (2004).
5. Jager RD, Mieler WF, Miller JW. Age related macular degeneration. N. Engl. J. Med. 358(24), 2606-2617 (2008).
6. de Jong PT. Age related macular degeneration. N. Engl. J. Med. 355(14), 1474-1485 (2006).
7. Kaarniranta K, Salminen A, Haapasalo A et al. Age-related macular degeneration (AMD): Alzheimer's disease in the eye? J. Alzheimers Dis. 24(4), 615-631 (2011).
8. Kaarniranta K, Salminen A, Eskelinen EL et al. Heat shock proteins as gatekeepers of proteolytic pathways-implications for age-related macular degeneration (AMD). Age. Res. Rev. 8, 128-139 (2009).
9. SanGiovanni JP, Chew EY, Agrón E et al. The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Arch. Ophthalmol. 126, 1274-1279 (2008).
10. Sin HP, Liu DT, Lam DS. Lifestyle modification, nutritional and vitamins supplements for age-related macular degeneration. Acta Ophthalmol. doi:10.1111/j.1755-3768.2011.02357.x (2012) (Epub ahead of print).
11. Kaarniranta K, Salminen A. NF-kappaB signaling as a putative target for omega-3 metabolites in the prevention of age-related macular degeneration (AMD). Exp. Gerontol. 44(11), 685-688 (2009).
12. Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica 227(Suppl. 1), 11-20 (2012).
13. CATT Research Group, Martin DF, Maguire MG et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364(20), 1897-1908 (2011).
14. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1419-1431 (2006).
15. Heier JS, Boyer D, Nguyen QD et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 118(6), 1098-1106 (2011).
16. The IVAN Study Investigators Writing Committee. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119(7), 1399-1411 (2012).
17. Algvere PV, Seregard S. Age-related maculopathy: pathogenetic features and new treatment modalities. Acta Ophthalmol. Scand. 80, 136-143 (2002).
18. Jarrett SG, Boulton ME. Antioxidant up-regulation and increased nuclear DNA protection play key roles in adaptation to oxidative stress in epithelial cells. Free Radic. Biol. Med. 38(10), 1382-1391 (2005).
19. Kaarniranta K, Ryhänen T, Karjalainen HM et al. Geldanamycin increases 4-hydroxynonenal (HNE)-induced cell death in human retinal pigment epithelial cells. Neurosci. Lett. 382(1-2), 185-190 (2005).
20. Kauppinen A, Niskanen H, Suuronen T, Kinnunen K, Salminen A, Kaarniranta K. Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells-Implications for age-related macular degeneration (AMD). Immunol. Lett. 147(1-2), 29-33 (2012).
21. Thampi P, Rao HV, Mitter SK et al. The 5HT1a receptor agonist 8-Oh DPAT induces protection from lipofuscin accumulation and oxidative stress in the retinal pigment epithelium. PLoS ONE 7(4), e34468 (2012).
22. Klettner A. Oxidative stress induced cellular signaling in RPE cells. Front. Biosci. 1(4), 392-411 (2012).
23. Kaarniranta K, Hyttinen JMT, Ryhänen T et al. Mechanisms of protein aggregation in the retinal pigment epithelial cells. Front. Biosci. 1(2), 1374-1384 (2010).
24. Blasiak J, Szaflik JP. DNA damage and repair in age-related macular degeneration. Front. Biosci. 1(16), 1291-1301 (2011).
25. Roth F, Bindewald A, Holz FG. Key pathologic pathways in age-related macular disease. Graefes Arch. Clin. Exp. Ophthalmol. 242(8), 710-716 (2004).
26. Algvere PV, Marshall J, Seregard S. Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol. Scand. 84(1), 4-15 (2006).
27. Kaemmerer E, Schutt F, Krohne TU et al. Effects of lipid peroxidation-related protein modifications on RPE lysosomal functions and POS phagocytosis. Invest. Ophthalmol. Vis. Sci. 48(3), 1342-1347 (2007).
28. Vives-Bauza C, Anand M, Shirazi AK et al. The age lipid A2E and mitochondrial dysfunction synergistically impair phagocytosis by retinal pigment epithelial cells. J. Biol. Chem.283(36), 24770-24780 (2008).
29. Finnemann SC, Leung LW, Rodriguez-Boulan E. The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid by the retinal pigment epithelium. Proc. Natl Acad. Sci. USA 99(6), 3842-3847 (2002).
30. Terman A, Kurz T, Navratil M et al. Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial-lysosomal axis theory of aging, Antiox. Redox. Signal. 12(4), 503-535 (2010).
31. Suzuki M, Kamei M, Itabe H et al. Oxidized phospholipids in the macula increase with age and in eyes with age-related macular degeneration Mol. Vis. 13, 772-778 (2007).
32. Kinnunen PK, Kaarniranta K, Mahalka AK. Protein-oxidized phospholipid interactions in cellular signaling for cell death: From biophysics to clinical correlations. Biochim. Biophys. Acta. 1818(10), 2446-2455 (2012).
33. Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. Nat. Cell Biol. 2(9), 814-822 (2010).
34. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signalling regulation. Curr. Opin. Cell. Biol. 22(2), 124-131 (2010).
35. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 147(4), 728-741 (2011).
36. Salminen A, Kaarniranta K. Regulation of the aging process by autophagy. Trends Mol. Med. 15(5), 217-224 (2009).
37. Harris H, Rubinsztein DC. Control of autophagy as a therapy for neurodegenerative disease. Nat. Rev. Neurol. 8(2), 108-117 (2011).
38. Itakura E, Kishi C, Inoue K et al. Beclin 1 forms two distinct phosphatidylinositol 3-kinase complexes with mammalian Atg14 and UVRAG. Mol. Biol. Cell 19(12), 5360-5372 (2008).
39. Sun Q, Fan W, Chen K et al. Identification of Barkor as a mammalian autophagy-specific factor for Beclin 1 and class III phosphatidylinositol 3-kinase. Proc. Natl Acad. Sci. USA 105(49), 19211-19216 (2008).
40. Ganley IG, Lam DH, Wang J et al. ULK1·ATG13·FIP200 complex mediates mTOR signaling and is essential for autophagy. J. Biol. Chem. 284(18), 12297-12305 (2009).
41. Hosokawa N, Hara T, Kaizuka T et al. Nutrient-dependent mTORCl association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol. Biol. Cell 20(7), 1981-1991 (2009).
42. Jung CH, Jun CB, Ro SH et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol. Biol. Cell 20(7), 1992-2003 (2009).
43. Mercer CA, Kaliappan A, Dennis PB. A novel, human Atg13 binding protein, Atg101, interacts with ULK1 and is essential for macroautophagy. Autophagy 5(5), 649-662 (2009).
44. Mari M, Griffith J, Rieter E et al. An Atg9-containing compartment that functions in the early steps of autophagosome biogenesis. J. Cell Biol. 190(6), 1005-1022 (2010).
45. Fujita N, Itoh T, Omori H et al. The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy. Mol. Biol. Cell 19(5), 2092-2100 (2008).
46. Hanada T, Noda NN, Satomi Y et al. The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy. J. Biol. Chem. 282(52), 37298-37302 (2007).
47. Pankiv S, Clausen TH, Lamark T et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 282(33), 24131-24145 (2007).
48. Korolchuk VI, Mansilla A, Menzies FM, Rubinsztein DC. Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 33(4), 517-527 (2009).
49. Mitter SK, Rao HV, Qi X et al. Autophagy in the retina: a potential role in age-related macular degeneration. Adv. Exp. Med. Biol. 723, 83-90 (2012).
50. Inoki K, Kim J, Guan KL. AMPK and mTOR in cellular energy homeostasis and drug targets. Annu. Rev. Pharmacol. Toxicol. 52, 381-400 (2012).
51. Wang AL, Lukas TJ, Yuan M et al. Autophagy and exosomes in the aged retinal pigment epithelium: possible relevance to drusen formation and age-related macular degeneration. PLoS ONE 24 e4160 (2009).
52. Ryhänen T, Hyttinen JM, Kopitz J et al. Crosstalk between Hsp70 molecular chaperone, lysosomes and proteasomes in autophagymediated proteolysis in human retinal pigment epithelial cells. J. Cell. Mol. Med. 13(9b), 3616-3631 (2009).
53. Viiri J, Hyttinen JM, Ryhänen T et al. p62/sequestosome 1 as a regulator of proteasome inhibitor-induced autophagy in human retinal pigment epithelial cells. Mol. Vis. 16, 1399-1414 (2010).
54. Laplante M, Sabatini DM. mTOR signaling at a glance. Cell Sci. 122(Pt 20), 3589-3594 (2009).
55. Hyttinen JM, Petrovski G, Salminen A et al. 5́-adenosine monophosphate-activated protein kinase-mammalian target of rapamycin axis as therapeutic target for age-related macular degeneration. Rejuvenation Res. 14(6), 651-660 (2011).
56. Wilkinson JE, Burmeister L, Brooks SV et al. Rapamycin slows aging in mice. Aging Cell. 11(4), 675-682 (2012) (2012).
57. Trüe O, Matthias P. Interplay between histone deacetylases and autophagy-from cancer therapy to neurodegeneration. Immunol. Cell Biol. 90(1), 78-84 (2012).
58. Bové J, Martínez-Vicente M, Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat. Rev. Neurosci. 12(8), 437-452 (2011).
59. Yang DS, Stavrides P, Mohan PS et al. Therapeutic effects of remediating autophagy failure in a mouse model of Alzheimer disease by enhancing lysosomal proteolysis. Autophagy 7(7), 788-789 (2011).
60. Sarkar S, Ravikumar B, Floto RA et al. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ. 16(1), 46-56 (2009).
61. Zhao C, Yasumura D, Li X et al. mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice. J. Clin. Invest. 121, 369-383 (2011).
62. Li Y, Huang D, Xia X, Wang Z et al. CCR3 and choroidal neovascularization. PLoS ONE 6, e17106 (2011).
63. Dejneka NS, Kuroki AM, Fosnot J et al. Systemic rapamycin inhibits retinal and choroidal neovascularizaion in mice. Mol. Vis. 10, 964-972 (2004).
64. Stahl A, Paschek L, Martin G et al. Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett. 582(20), 3097-3102 (2008).
65. Kokkinopoulos I, Shahabi G, Colman A et al. Mature peripheral RPE cells have an intrinsic capacity to proliferate; a potential regulatory mechanism for age-related cell loss. PLoS ONE 6, e18921 (2011).
66. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 25(18), 1895-1908 (2011).
67. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13(9), 1016-1023 (2011).
68. Momcilovic M, Hong SP, Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J. Biol. Chem. 281(35), 25336-25343 (2006).
69. Hawley SA, Selbert MA, Goldstein EG et al. 5-AMP activates the AMP-activated protein kinase cascade, and Ca2+/calmodulin activates the calmodulin-dependent protein kinase I cascade, via three independent mechanisms. J. Biol. Chem. 270(45), 27186-27191 (1995).
70. Hong SP, Leiper FC, Woods A et al. Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc. Natl Acad. Sci. USA 100(15), 8839-8843 (2003).
71. Warden SM, Richardson C, O'Donnell J Jr et al. Post-translational modifications of the b-1 subunit of AMP-activated protein kinase affect enzyme activity and cellular localization. Biochem. J. 354(Pt 2), 275-283 (2001).
72. Oakhill JS, Chen ZP, Scott JW et al. b-Subunit myristoylation is the gatekeeper for initiating metabolic stress sensing by AMP-activated protein kinase (AMPK). Proc. Natl Acad. Sci. USA 107(45), 19237-19241 (2010).
73. McBride A, Ghilagaber S, Nikolaev A et al. The glycogen-binding domain on the AMPK b subunit allows the kinase to act as a glycogen sensor. Cell Metab. 9(1), 23-34 (2009).
74. Kaarniranta K, Salminen A. Age-related macular degeneration: activation of innate immunity system via pattern recognition receptors. J. Mol. Med. 87(2), 117-123 (2009).
75. Behrends C, Sowa ME, Gygi SP et al. Network organization of the human autophagy system. Nature 466(7302), 68-76 (2010).
76. Egan DF, Shackelford DB, Mihaylova MM et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331(6016), 456-461 (2011).
77. Kim J, Kundu M, Viollet B et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 13(2), 132-141 (2011).
78. Qin S, Rodrigues GA. Differential roles of AMPKa1 and AMPKa2 in regulating 4-HNE-induced RPE cell death and permeability. Exp. Eye Res. 91(6), 818-824 (2010).
79. Qin S, De Vries GW. a2 But not a1 AMP-activated protein kinase mediates oxidative stress-induced inhibition of retinal pigment epithelium cell phagocytosis of photoreceptor outer segments. J. Biol. Chem. 283(11), 6744-6751 (2008).
80. Herrero-Martín G, Høyer-Hansen M, García- García C et al. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 28(6), 677-685 (2009).
81. Yamamoto H, Schoonjans K, Auwerx J. Sirtuin functions in health and disease. Mol. Endocrinol. 21(8), 1745-1755 (2007).
82. Hoff KG, Wolberger C. Getting a grip on O-acetyl-ADP-ribose. Nat. Struct. Mol. Biol. 12(7), 560-561 (2005).
83. Michishita E, McCord RA, Berber E et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 452(7186), 492-496 (2008).
84. Kawahara TL, Michishita E, Adler AS et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell. 136(1), 62-74 (2009).
85. Nakagawa T, Lomb DJ, Haigis MC et al. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 137(3), 560-570 (2009).
86. Du J, Zhou Y, Su X et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science 334(6057), 806-809. (2011).
87. Peng C, Lu Z, Xie Z et al. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol. Cell. Proteomics. 10(12), M111.012658 (2011).
88. Blander G, Bhimavarapu A, Mammone T et al. SIRT1 promotes differentiation of normal human keratinocytes. J. Invest. Dermatol. 129(1), 41-49 (2009).
89. Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug Discov. 7(10), 841-853 (2008).
90. Guarente L. Franklin H. Epstein lecture: sirtuins, aging, and medicine. N. Eng. J. Med. 364(23), 2235-2244 (2009).
91. Wang Y, Liang Y, Vanhoutte PM. SIRT1 and AMPK in regulating mammalian senescence: a critical review and a working model. FEBS Lett. 585(7), 986-994 (2011).
92. Cantó C, Gerhart-Hines Z, Feige JN et al. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458(7241), 1056-1060 (2009).
93. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase-development of the energy sensor concept. J. Physiol. 574(Pt 1), 7-15 (2006).
94. Beauloye C, Bertrand L, Horman S et al. AMPK activation, a preventive therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc. Res. 90(2), 224-233 (2011).
95. Fulco M, Cen Y, Zhao P et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev. Cell 14(5), 661-673 (2008).
96. Lan F, Cacicedo JM, Ruderman N et al. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J. Biol. Chem. 283(41), 27628-27635 (2008).
97. Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{a}. J. Biol. Chem. 280(16), 16456-16460 (2005).
98. Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim. Biophys. Acta 1813(7), 1269-1278 (2011).
99. Palacios OM, Carmona JJ, Michan S et al. Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1alpha in skeletal muscle. Aging 1(9), 771-783 (2009).
100. Shi T, Wang F, Stieren E, Tong Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J. Biol. Chem. 280(14), 13560-13567 (2005).
101. Shi T, Fan GQ, Xiao SD. SIRT3 reduces lipid accumulation via AMPK activation in human hepatic cells. J. Dig. Dis. 11(1), 55-62 (2010).
102. Kong X, Wang R, Xue Y et al. Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS ONE 5(7), e11707 (2010).
103. Giralt A, Hondares E, Villena JA et al. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha controls transcription of the Sirt3 gene, an essential component of the thermogenic brown adipocyte phenotype. J. Biol. Chem. 286(19), 16958-16966 (2011).
104. Pillai VB, Sundaresan NR, Kim G et al. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J. Biol. Chem. 285(5), 3133-3144 (2010).
105. Law IK, Liu L, Xu A et al. Identification and characterization of proteins interacting with SIRT1 and SIRT3: implications in the anti-aging and metabolic effects of sirtuins. Proteomics 9(9), 2444-2456 (2009).
106. Hallows WC, Lee S, Denu JM. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc. Natl Acad. Sci. USA 103(27), 10230-10235 (2006).
107. Sundaresan NR, Gupta M, Kim G et al. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Invest. 119(9), 2758-2771 (2009).
108. Lynch CJ, Shah ZH, Allison SJ et al. SIRT1 undergoes alternative splicing in a novel auto-regulatory loop with p53. PLoS ONE 5(10), e13502 (2010).
109. Salminen A, Kaarniranta K. SIRT1: regulation of longevity via autophagy. Cell Signal. 21(9), 1356-1360 (2009).
110. Tasdemir E, Maiuri MC, Orhon I et al. p53 represses autophagy in a cell cycle-dependent fashion. Cell Cycle 7(19), 3006-3011 (2008).
111. Tavernarakis N, Pasparaki A, Tasdemir E et al. The effects of p53 on whole organism longevity are mediated by autophagy. Autophagy 4(7), 870-873 (2008).